Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia

T cell acute lymphoblastic leukemia (T-ALL) is caused by clonal expansion of variant T cell progenitors and is considered as a high risk leukemia. Contemporary single chemotherapy has a limited effect due to dynamic and versatile properties of T-ALL. Here IRAK1/4 inhibitor and ABT-737 were co-encaps...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Nanomedicine
Egile Nagusiak: Wu, Xiaoyan, Wang, Lin, Qiu, Yining, Zhang, Bingyu, Hu, Zhenhua, Jin, Runming
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2017
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5673049/
https://ncbi.nlm.nih.gov/pubmed/29184402
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/IJN.S146875
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak